Skip to main content

Table 1 MTUHA data description

From: Monitoring patient care through health facility exit interviews: an assessment of the Hawthorne effect in a trial of adherence to malaria treatment guidelines in Tanzania

  Overall Non-survey days Survey days
  n % n % n %
  Median (IQR) Median IQR Median (IQR)
Day characteristics N = 1,520   N = 829   N = 691  
Study period
 1 – February-April 2011 448 29.5 % 275 33.2 % 173 25.0 %
 2 – June-July 2011 539 35.5 % 293 35.3 % 246 35.6 %
 3 – January-March 2012 533 35.1 % 261 31.5 % 272 39.4 %
Number of days per health facility
 Median (IQR) 85 (77–95) 47 (40–53) 39 (36–41)
Number of patient records per day
 Median (IQR) 11 (7–16) 11 (7–16) 12 (8–17)
Patients characteristics N = 19,579   N = 9,834   N = 9,745  
Age (years) (N = 19,340)
 Median, IQR 12 (3–36) 12 (3–35) 13 (3–38)
Gender (N = 19,530)
 Male 8,366 42.8 % 4,229 43.2 % 4,137 42.5 %
 Female 11,164 57.2 % 5,569 56.8 % 5,595 57.5 %
Fevera (N = 9,785)
 Yes 4,521 46.2 % 1,803 41.5 % 2,718 50 %
Diagnostic and treatment N = 19,579   N = 9,834   N = 9,745  
RDT recorded
 Yes 3,821 19.5 % 1,811 18.4 % 2,010 20.6 %
RDT result (n = 3,821)
 Positive 199 5.2 % 90 5.0 % 109 5.4 %
 Negative 3,622 94.8 % 1,721 95.0 % 1,901 94.6 %
AM prescription to RDT positive (n = 199)
 No AM prescription recorded 52 26.1 % 21 23.3 % 31 28.4 %
ALu 85 42.7 % 46 51.1 % 39 35.8 %
Other AM 62 31.2 % 23 25.6 % 39 35.8 %
AM prescribed to RDT negative (n = 3,622)
 No AM prescription recorded 3,294 90.9 % 1,553 90.2 % 1,741 91.6 %
 ALu 275 7.6 % 148 8.6 % 127 6.7 %
 Other AM 53 1.5 % 20 1.2 % 33 1.7 %
AM prescribed without RDT result (n = 15,758)
 No AM prescription recorded 15,366 97.5 % 7,813 97.4 % 7,553 97.6 %
 ALu 275 1.8 % 160 2.0 % 115 1.5 %
 Other AM 117 0.7 % 50 0.6 % 67 0.9 %
  1. Frequencies reported next to characteristics when different from total
  2. aPresence of fever was not part of routine data collection and was not always collected
  3. MTUHA Mfumo wa Taarifa za Huduma za Afya (health management information system), IQR 1st and 3rd quartile, ALu artemether-lumefantrine, AM antimalarial drug